Barinthus Biotherapeutics plc.BRNSEarnings & Financial Report
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.
BRNS Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-15.1M
Net Profit
$-14.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.36
Barinthus Biotherapeutics plc. Q3 FY2025 Financial Summary
Barinthus Biotherapeutics plc. reported revenue of $0 for Q3 FY2025, with a net profit of $-14.6M (down 79.5% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-14.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Barinthus Biotherapeutics plc. Annual Revenue by Year
Barinthus Biotherapeutics plc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $15.0M).
Barinthus Biotherapeutics plc. Quarterly Revenue & Net Profit History
Barinthus Biotherapeutics plc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-14.6M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $15.0M | — | $-8.1M | -54.2% |
| Q2 FY2024 | $0 | — | $-16.9M | N/A |
| Q1 FY2024 | $0 | — | $-15.5M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $15.0M | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Assets | $199.5M | $186.7M | $188.7M | $160.3M | $109.2M |
| Liabilities | $27.5M | $30.0M | $29.2M | $30.2M | $24.6M |
| Equity | $171.8M | $156.6M | $159.3M | $130.0M | $84.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-11.8M | $-12.0M | $-18.2M | $-28.9M | $-10.7M |